Laboratory studies and clinical evaluation of 7432-S in respiratory infections

7432-S, a new cephem antibiotic, was basically and clinically evaluated with the following results: 1) Antimicrobial activity: The minimum inhibiratory concentration (MICs) of 7432-S against 134 strains consisting of 12 standard strains and 122 clinical isolates (6 species) were compared with those of cefaclor (CCL) and cefotiam (CTM). Against Staphylococcus aureus, Streptococcus pneumoniae 7432-S was five tubes less potent in antibacterial activity than CCL and CTM, but equal against Branhamella catarrhalis. On the other hand, 7432-S was four to eight tubes more potent than either antibiotic against Haemophilus influenzae and the same or one tube more potent against Klebsiella pneumoniae. None of the three antibiotics showed antibacterial activity against Pseudomonas aeruginosa. 2) Clinical efficacy: 7432-S was administered at a daily dose of 300 or 400 mg for 3∼14 days to 11 patients with various respiratory infections. Clinical response was good in 7, fair in 3, and poor in 1. The overall efficacy rate was 63.696 (7/11 cases). Subjective and objective symptoms, hematological and biochemical data and renal functions were checked before and after administration of 7432-S, and one patient showed minim elevation of S-GPT. We therefore conclude that 7432-S is a useful antibiotic in treating respiratory infections.